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Abstract
Background: Genotyping of hepatitis C virus (HCV) has become an essential tool for prognosis and prediction of
treatment duration. The aim of this study was to compare two HCV genotyping methods: reverse hybridization line
probe assay (LiPA v.1) and partial sequencing of the NS5B region.
Methods: Plasma of 171 patients with chronic hepatitis C were screened using both a commercial method (LiPA
HCV Versant, Siemens, Tarrytown, NY, USA) and different primers targeting the NS5B region for PCR amplification
and sequencing analysis.
Results: Comparison of the HCV genotyping methods showed no difference in the classification at the genotype
level. However, a total of 82/171 samples (47.9%) including misclassification, non-subtypable, discrepant and
inconclusive results were not classified by LiPA at the subtype level but could be discriminated by NS5B
sequencing. Of these samples, 34 samples of genotype 1a and 6 samples of genotype 1b were classified at the
subtype level using sequencing of NS5B.
Conclusions: Sequence analysis of NS5B for genotyping HCV provides precise genotype and subtype identification
and an accurate epidemiological representation of circulating viral strains.
Keywords: HCV, genotyping, NS5B region, 5’UTR
Background
The Hepatitis C virus (HCV) genome sequence is highly
variable. Six major types and approximately 80 subtypes
have been recognized since it was first identified [1]. The
nucleotide level differs by 31% to 33% among genotypes
and by 20% to 25% among subtypes [2]. Genetic variation
throughout the genome is not uniform. The region
encoding envelope glycoproteins was the most variable
when compared to the highly conserved 5’ untranslated
region (5’UTR) [3]. Most of the commercially available
genotyping methods are based on the detection of the
conserved bases within the 5’UTR region. However, the
ability of the 5’UTR nucleotide sequence to discriminate
v i r u si s o l a t e sa tt h es u b t y p el evel is controversial, and
alternative regions have been proposed for genotyping
[4]. The widely accepted reference method for HCV gen-
otyping is the NS5B region sequencing [5]. Therefore,
the aim of the present study was to compare a genotyp-
ing method based on partial sequencing of the NS5B
region to a commercial method based on the 5’ UTR
region (LiPA) using plasma samples obtained from Brazi-
lian patients.
Materials and methods
Plasma samples
A total of 171 plasma samples representing HCV geno-
types 1, 2, 3, 4, and 5 were used in this study. All samples
had been previously genotyped by line probe assay
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(Siemens, Tarrytown, NY, USA) after amplification of
244 bp of the 5’UTR fragment, which had been generated
using the Amplicor
® Hepatitis C Virus (HCV) Test, ver-
sion 2.0 (Roche, Branchburg, NJ, USA) according to the
manufacturer’s instructions.
This study protocol was approved by the Ethics Com-
mittee of the University of São Paulo (CAAE -
2546.0.015.000-05).
RNA extraction
RNA extraction was performed using the NucliSENS
Magnetic Extraction Reagents (bioMérieux, Boxtel, the
Netherlands). A total of 200 ml of plasma was added to
the lysis buffer and incubated for 10 minutes at room
temperature. Magnetic silica particles were used for
nucleic acid binding for 10 minutes at room temperature.
Silica particles were washed with different buffers, and
the NucliSENS miniMAG apparatus was used to collect
and wash the particles. The nucleic acids were released
from the silica particles using 60 ml of elution buffer and
by heating the samples to 60°C for five minutes.
RT-PCR
The synthesis of cDNA was performed essentially as pre-
viously described [6]. For reverse transcription, 40 ml of
RNA was added to the reaction mixture [3 ml of random
primers (7.5 ng/ml) and 36 ml of DEPC-H2O] and incu-
bated at 70°C for 10 minutes. Then, 24 ml of Reverse
Transcription mix [5X buffer, 0.1 M DTT, 10 mM dNTPs,
30 U/ml RNase Out, and 200 U/ml M-MLV RT (Invitro-
gen, Carlsbad, CA, USA)] were added. Reverse transcrip-
tion was performed using the GeneAmp PCR Systems
9700 (Applied Biosystems, Foster, CA, USA) using the fol-
lowing conditions: 25°C for 15 min, 37°C for 62 min, 95°C
for 15 min, and a final hold at 10°C.
Amplification of the HCV cDNA
All primers described in this study were designed based
on the NS5B region consensus sequences, which were
obtained upon alignment of the data provided by the Los
Alamos National Laboratory http://hcv.lanl.gov/content/
sequence/HCV/ToolsOutline.html.
Table 1 includes details for the primers (Invitrogen) that
were used in the PCR amplification of the NS5B region.
Each PCR reaction contained 10X buffer [200 mM Tris-
HCl (pH 8.4), 500 mM KCl], 1.5 mM MgCl2,1 0m M
dNTPs, 1 μM of each primer, 2.5 UI of Platinum Taq
DNA Polymerase High Fidelity (Invitrogen) and 5 μlo f
the cDNA to be tested in a final volume of 50 μl that was
obtained using DEPC-treated H2O. PCR was performed in
the GeneAmp PCR System 9700 (Applied Biosystems)
using the following amplification conditions: 5 min at
94°C; 35 cycles at 95°C for 30 s, 60.5°C for 1 min for
primer NS5B2F/NS5B2R, 56°C for 45 s for primer F56_1-
3/R56_1-3, or 58°C for 45 s for primer GEN2FSN/
GEN2RSN, and 72°C for 1 min; 72°C for 10 min; and a
final hold at 10°C.
Nucleotide sequencing of NS5B region
PCR products were purified using the PureLink™ PCR
Purification Kit (Invitrogen), quantified using the Kodak
Digital Science Analysis System 120 (Rochester, NY,
USA) and diluted to 20 ng/μl. Sequencing reactions
were performed in both directions using the Big Dye
terminator version 3.2 (Applied Biosystems), and the
products were detected using the ABI 3130 Genetic
Analyzer (Applied Biosystems).
Sequence analysis
Nucleotide sequences from HCV strains were edited
using Codon Code (Codon Code Corporation, Dedham,
MA, USA) and imported to BioEdit [7], which was used
to align the sequences to a reference panel of reported
sequences provided by the Los Alamos National Labora-
toryhttp://hcv.lanl.gov/content/sequence/HCV/Tool-
sOutline.html.
A total of 171 HCV NS5B sequences of different geno-
types that were identified in this study were submitted to
GenBank and can be retrieved under the accession num-
bers EF136859 to EF136882 and FJ159697 to FJ159845.
Phylogenetic analysis
An internal fragment of 216 nucleotides within the PCR
products that were generated for sequencing (positions
1223-1438 in the NS5B region according to the reference
sequence H77, GenBank accession number NC004102)
was used for phylogenetic analysis with 138 of the 171
(80.7%) samples. Nucleotide distances were computed
with MEGA version 4.0 [8] using the r-distance algorithm.
Phylogenetic trees were inferred using the neighbor join-
ing method. Robustness of the tree branches was tested
using bootstrap analysis (1000 replicates).
Results
HCV genome amplification
The primer pair NS5B2F/NS5B2R was efficient in amplify-
ing most of genotypes 1 to 5. However, these primers
failed to amplify six samples of genotype 2. To amplify
these samples, we designed a specific primer pair
(GEN2FSN/GEN2RSN). Among these amplified samples,
five were classified as genotype 2 c and one as 2b.
Performance comparison of HCV genotyping using 5’UTR
(LiPA) and NS5B sequence analysis
Comparison of HCV genotyping was based on NS5B
sequence analysis and LiPA (5’UTR) and showed no dif-
ference in the classification of all 171 samples (Table 2).
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for 47.9% (82/171) of the subtyping results between
LiPA and NS5B sequencing (Table 3). LiPA did not
assign subtypes for 40 samples of genotype 1, which
were classified as genotype 1a (34 samples) and geno-
type 1b (6 samples) by partial NS5B sequencing. Four
samples that were classified by LiPA as genotype 1b
w e r eg r o u p e da sg e n o t y p e1 ab yN S 5 Bs e q u e n c i n g .
Among 26 genotype 2 samples, LiPA classified five sam-
ples as genotype 2b. Forty-two genotype 3 samples were
correctly typed as 3a by LiPA, which was confirmed by
NS5B sequencing.
Inconclusive genotypes
LiPA classified 11 samples as genotype 1a/1b, which were
further subtyped as genotypes 1a (7/11) and 1b (4/11) by
NS5B sequencing. Two samples yielded LiPA patterns
that were categorized as genotype 2a/2c. However, NS5B
sequencing subtyped these samples as genotype 2 c
(Table 3).
Phylogenetic analysis
Discrepancies were not found when the results of partial
NS5B sequencing and phylogenetic analysis of 138 sam-
ples were compared.
Discussion
Hepatitis C virus genotyping assays are usually based on
the sequence analysis of an amplified segment of the
genome, which is commonly the 5’ untranslated region.
Currently, 5’UTR based assays are reasonably accurate
with more than 95% concordance with genotypes that
have been identified by nucleotide sequencing of the
NS5B region or other coding regions of the HCV gen-
ome [9]. In our study, LiPA and NS5B sequencing
s h o w e d1 0 0 %a g r e e m e n ta tt h et y p el e v e l .T h e s er e s u l t s
are similar to those reported by another study using the
5’UTR with a type agreement of 99.5% [10]. Another
study with 357 samples from French blood donors has
demonstrated 100% agreement between 5’UTR and
NS5B sequence analysis regarding type classification
[11]. However, depending on the geographical region,
genotype identification based on 5’UTR may be unreli-
able because some genotype 6 variants that have been
found in Southeast Asia have identical 5’UTR sequences
to those of genotypes 1a or 1b [12]. In Brazil, the most
prevalent HCV genotypes are 1, 2 and 3, whereas geno-
types 4 and 5 are rarely identified and genotype 6 has
not been previously described [13].
When we compared the subtyping results of LiPA and
partial NS5B sequencing, we found 47.9% (82/171) of
misclassification among samples, including non-subtyp-
able discrepant and inconclusive results. LiPA could not
discriminate 39.6% (40/101) of the genotype 1 samples at
the subtype level. LiPA misclassified three samples of
genotype 1b as genotype 1a and four samples of genotype
1a as genotype 1b. LiPA did not accurately discriminate
between genotypes 1a and 1b, which may be attributed to
the lack of discriminating power of LiPA probes 5 and 6.
The difference between these probes covers a single
nucleotide change in the HCV genome, which is an A to
G transition at position -99 within the 5’UTR. There is
evidence that this transition represents a sequence poly-
morphism that cannot be used to differentiate between
subtypes 1a and 1b [14]. Accordingly, we found that
LiPA yielded inconclusive results for 11 genotype 1 sam-
ples, which were classified as genotype 1a/1b.
Concerning genotype 2, 26 samples were investigated
in our study. The small sample size is due to the low
Table 1 PCR primers used in NS5B-based in-house methods
Primer name Genotype Sequence Product Position Region NS5B*
NS5B2F All genotypes 5’-TTCACGGAGGCTATGACYAGG-3’ 688 bp 1017-1038
NS5B-2R 5’-CGGGCATGMGACASGCTGTGA-3’ 1704-1683
F56_1-3 1 and 3 5’-CACACTCCAGTYAAYTCCTGG-3’ 241 bp 1204-1224
R56_1-3 5’-CWMCTGGAGAGTAACTGTGGAG-3’ 1444-1423
GEN2FSN 2 5’-GACACTCCCCTGTCAATTCWTGG-3’ 120 bp 1202-1224
GEN2RSN 5’-TGGTYCAGAGTGTCYTGGGC-3’ 1321-1313
*1a_.H77.NC_004102 - reference sequence that was used to calculate the positions of the NS5B region.
Table 2 Comparison of HCV genotyping results from LiPA
(5’UTR) and partial NS5B sequencing
LiPA type Number of specimens with NS5B sequencing Total
1a 1b 2a 2b 2c 3a 4a 5a
1 34 6 40
1a 10 3 13
1b 43 2 3 6
1a/1b 74 1 1
2 11 17 1 9
2b 55
2a/2c 22
3a 42 42
3a/3b 11
4 11
5 11
Total 55 45 1 16 9 43 1 1 171
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4%). In our study, only five of the 26 genotype 2 sam-
ples were simultaneously subtyped as 2b by LiPA and
NS5B sequence analysis. The 21 remaining genotype 2
samples were not accurately subtyped by LiPA. After
performing the sequence analysis of the NS5B region,
11 of these 21 samples were classified as genotype 2b,
n i n es a m p l e sa sg e n o t y p e2ca n do n es a m p l ea sg e n o -
type 2a. This poor resolution was expected because
LiPA targets 5’UTR, which may result in incorrect iden-
tification of subtypes 2a and 2 c due to the lack of
nucleotide polymorphisms [15]. Similarly, a previous
study has reported that 61% of the subtypes of genotype
2 were misclassified by 5’UTR-based genotyping in
France [11]. Another study has compared genotyping
using real-time PCR targeting the NS5B region and
LiPA v.1.0 and has shown that LiPA did not subtype 68
of the 295 samples (23%) [16].
The low reported prevalence of mixed HCV genotype
infection suggests that this type of infection is a rare
event and is influenced by the population that is studied
and the genotyping method that is employed [17]. A
study with 600 patients has shown that 2.2% of patients
displayed evidence of mixed infections. These sera have
been screened using sequencing and serological assays in
parallel [18]. Accordingly, only two laboratories have cor-
rectly identified one of the three samples containing
mixed HCV genotypes in a national evaluation study that
was conducted in France [19]. Cases of mixed HCV gen-
otypes have not been confirmed in our study. Although
all of the samples were characterized as infected based on
a single genotype, direct sequencing is not the gold stan-
dard method to detect mixed infection. The best
approach to reliably detect mixed-genotype infections is
PCR amplification followed by cloning of the PCR pro-
ducts or the use of next-generation sequencing methods.
Unfortunately, this approach is unfeasible in a routine
clinical setting [20]. The results that are reported herein
are similar to those found in another study that has been
conducted in Brazil using sequencing to genotype 1,688
samples from chronic HCV patients, who did not show
evidence of mixed infection [21].
In our study, the 5’UTR-based genotyping method
(LiPA) showed higher efficiency than the NS5B region
to generate PCR amplification products. Primers target-
ing the 5’UTR, which is a highly conserved region, pro-
duce fewer false negative results in PCR reactions for
HCV detection. The major factor to be considered when
evaluating the generation of false negative PCR results is
the existence of different strains or subtypes of HCV
[22]. Because the polymorphic positions are not homo-
genously distributed within the NS5B region, difficulty
to generate amplicons may be due to inadequate primer
design, choice of highly polymorphic annealing
sequences or low viral load [19].
Currently, there is a new available commercial version of
LiPA (v.2), which contains probes targeting both the
5’U T Ra n dt h ec o r er e g i o n so ft h eH C Vg e n o m e ,w h i c h
improves the accuracy of subtyping, particularly regarding
the discrimination between subtypes 1a and 1b. By the
time this study was conducted, this version was not avail-
able for use in Brazil.
In the future, a protective vaccine and the availability of
HCV-specific antiviral drugs that are based on proteases or
polymerase inhibitors will probably require genotyping at
the subtype level. This genotyping approach will improve
our understanding of the genetic diversity of HCV. Geno-
typing methods that are based on the 5’UTR are important
tools for routine clinical purposes because they are suffi-
ciently precise at the genotype level. Our results show that
HCV genotyping using partial NS5B sequence analysis is
an efficient method that allows accurate discrimination of
Table 3 Clinical samples with discrepant subtyping results between LiPA(5’UTR) and partial NS5B sequencing
No. of samples LiPA (5’UTR) NS5B sequencing
Non-subtyped Discrepant results Inconclusive
34 1 1a
61 1b
41 b 1 a
31 a 1 b
7 1a/1b 1a
4 1a/1b 1b
1 3a/3b 3a
11 2 2b
72 2c
12 2a
2 2a/2c 2c
14 4a
15 5a
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cular epidemiology of HCV.
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